Seres Therapeutics (MCRB) EBIT Margin (2016 - 2026)

Seres Therapeutics has disclosed EBIT Margin across 10 years of filings, most recently posting 2890.35% for Q2 2026.

• In Q2 2026, EBIT Margin changed N/A year-over-year to 2890.35%; the TTM figure through Jun 2026 stood at 4462.77% (changed N/A YoY), while the FY2025 annual figure was 11910.14%, changed N/A from the prior year.
• EBIT Margin came in at 2890.35% for Q2 2026 at Seres Therapeutics, up from 5839.94% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 39.16% in Q2 2023 to a low of 14382.58% in Q3 2023.
• Average EBIT Margin over 4 years is 4852.2%, with a median of 4079.07% recorded in 2022.
• The largest YoY upside for EBIT Margin was 524681 bps in 2023 against a maximum downside of 1266635 bps in 2023.
• Over 4 years, EBIT Margin stood at 177.54% in 2022, then soared by 117 bps to 29.32% in 2023, then sank by 15187 bps to 4423.97% in 2025, then surged by 35 bps to 2890.35% in 2026.
• Per Business Quant data, the three most recent EBIT Margin figures were 2890.35% in Q2 2026, 5839.94% in Q1 2026, and 4423.97% in Q4 2025.